Explore 3 Stock Ideas & Industry Insights Download Free Report

Stocks

Applied Materials (NASDAQ:AMAT) Reports Q1 In Line With Expectations But Inventory Levels Increase

Semiconductor machinery manufacturer Applied Materials (NASDAQ:AMAT) met Wall Street’s revenue expectations in Q1 CY2025, with sales up 6.8% year on year to $7.1 billion. The company expects next quarter’s revenue to be around $7.2 billion, coming in 0.5% above analysts’ estimates. Its non-GAAP profit …

EODHD | 16 May 2025

Solid Biosciences Reports First Quarter 2025 Financial Results and Provides Business Updates

- Duchenne (SGT-003): Participant dosing ongoing in the Phase 1/2 INSPIRE DUCHENNE trial; Solid on track to discuss accelerated pathways with U.S. FDA later in 2025 - - FA (SGT-212): Dosing of first participant anticipated in the second half of 2025 - - CPVT …

EODHD | 16 May 2025

Birchtech Reports First Quarter 2025 Financial Results

First Quarter 2025 Revenues Totaled $3.2 Million, With Gross Margins Increasing 350 bps to 38.3% CORSICANA, Texas, May 15, 2025 (GLOBE NEWSWIRE) -- Birchtech Corp. (TSX: BCHT) (OTCQB: BCHT) ("Birchtech" or the "Company"), a leader in specialty activated carbon technologies for sustainable air and …

EODHD | 16 May 2025

AvePoint to Participate in June Investor Conferences

AvePoint, Inc. JERSEY CITY, N.J., May 15, 2025 (GLOBE NEWSWIRE) -- AvePoint (Nasdaq: AVPT), the global leader in data security, governance and resilience, today announced that members of the Company’s executive management team will present at the William Blair 45th Annual Growth Stock Conference …

EODHD | 16 May 2025

Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

Emrosi™ commercial launch initiated for the treatment of inflammatory lesions of rosacea in adults Fortress subsidiary Checkpoint Therapeutics to be acquired by Sun Pharma; special meeting of Checkpoint stockholders to approve the transaction to take place on May 28, 2025 FDA accepted New Drug …

EODHD | 16 May 2025

Crinetics to Present New Research on Paltusotine, Atumelnant and Unmet Needs in Acromegaly Treatment at the American Association of Clinical Endocrinology Annual Meeting 2025

Crinetics Pharmaceuticals, Inc. New Analysis Shows Treatment with Investigational Paltusotine Resulted in Rapid and Durable IGF-1 Control in Surgically Naïve Acromegaly Patients Additional Research Includes Acromegaly Symptom Burden and Standard-of-Care Discontinuation Rates SAN DIEGO, May 15, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: …

EODHD | 16 May 2025

Dragonfly Energy Reports First Quarter 2025 Results

First Quarter Net Sales and Adjusted EBITDA Above Guidance OEM Net Sales Increased 11% Year-Over-Year Corporate Optimization Program Enhances Operational Efficiencies Guides to Second Quarter Net Sales of Approximately $14.8 Million First Quarter 2025 Financial Highlights (All comparisons made are against the prior-year period) …

EODHD | 16 May 2025

Hormel Foods Announces Retirement of Scott Aakre, Group Vice President and Chief Marketing Officer for Retail, Following a Distinguished 35-year career

Aakre extends his service to the company by joining Hormel Foods board of directors AUSTIN, Minn., May 15, 2025 /PRNewswire/ -- Hormel Foods Corporation (NYSE: HRL), a Fortune 500 global branded food company, announced that Scott Aakre, group vice president and chief marketing officer …

EODHD | 16 May 2025

iPower Reports Fiscal Third Quarter 2025 Results

RANCHO CUCAMONGA, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- iPower Inc. (Nasdaq: IPW) (“iPower” or the “Company”), a tech and data-driven ecommerce services provider and online retailer, today announced its financial results for the fiscal third quarter ended March 31, 2025. Fiscal Q3 2025 …

EODHD | 16 May 2025

Neurocrine Biosciences Presents Data on Improvements in Physiologic Glucocorticoid Dosing and Select Reproductive Hormones in Patients with Classic Congenital Adrenal Hyperplasia Taking CRENESSITY™ (crinecerfont)

90% of Pediatric Participants on CRENESSITY versus 21% on Placebo Achieved ≥1 Threshold for Androstenedione Reduction or Glucocorticoid Reduction Observed Rates of Select Reproductive Hormone Normalization in Adult Males Taking CRENESSITY with Substantial Glucocorticoid Dose Reductions Findings Presented at the 2025 American Association of …

EODHD | 16 May 2025